Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALADIN: Pembrolizumab + FP with short-course radiotherapy for unresectable esophageal cancer
jRCT1031250183Phase 2Recruiting
- Start
- Jul 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, cisplatin and fluorouracil in Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenosquamous carcinoma (ASC) and esophageal basaloid squamous cell carcinoma (BSCC). Primary endpoint: Two-year survival rate. Started Jul 2025; status: recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenosquamous carcinoma (ASC)esophageal basaloid squamous cell carcinoma (BSCC)
Beyond the preview
Go deeper on jRCT1031250183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250183.